Status In progress
Process CDF Review
ID number 3788

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 March 2021 In progress. AstraZeneca has informed NICE that it will now participate in a CDF guidance review of olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788] following a period of managed access. The CDF guidance review will be rescheduled into the work programme and the updated review timelines will be communicated once known.
11 January 2021 Suspended. AstraZeneca has informed NICE that it will not provide an evidence submission for the guidance review of olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788] following a period of managed access. Therefore, we are suspending the appraisal and termination guidance is in development.
24 September 2020 Invitation to participate
03 August 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance